Esketamine Kalceks for Treatment-resistant depression
Quick answer: Esketamine Kalceks is used for Treatment-resistant depression as part of a nmda receptor antagonist (antidepressant) treatment regimen. S-enantiomer of ketamine, a non-competitive NMDA receptor antagonist modulating glutamatergic neurotransmission The specific dosing for Treatment-resistant depression is determined by your prescriber based on individual factors.
Why is Esketamine Kalceks used for Treatment-resistant depression?
Esketamine Kalceks belongs to the NMDA receptor antagonist (antidepressant) class. S-enantiomer of ketamine, a non-competitive NMDA receptor antagonist modulating glutamatergic neurotransmission This action makes it useful for treating or managing Treatment-resistant depression in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Esketamine Kalceks is the right choice for a specific patient depends on the type and severity of Treatment-resistant depression, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Treatment-resistant depression
Common adult dosing range: 56-84 mg intranasal twice weekly (induction). The actual dose for Treatment-resistant depression depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Esketamine Kalceks medicine page.
What to expect
Esketamine Kalceks treatment for Treatment-resistant depression typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Treatment-resistant depression
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Esketamine Kalceks is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all NMDA receptor antagonist (antidepressant) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Esketamine Kalceks
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Esketamine Kalceks full prescribing information · All NMDA receptor antagonist (antidepressant) alternatives
Frequently asked questions
How effective is Esketamine Kalceks for Treatment-resistant depression?
Effectiveness varies by individual response, dose, and severity. Esketamine Kalceks is one of several treatment options for Treatment-resistant depression, supported by clinical evidence within the nmda receptor antagonist (antidepressant) class. Discuss expected response with your prescriber.
How long do I need to take Esketamine Kalceks for Treatment-resistant depression?
Treatment duration depends on the nature of Treatment-resistant depression — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Esketamine Kalceks when used for Treatment-resistant depression?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Esketamine Kalceks for Treatment-resistant depression?
Yes. Multiple medicines and non-drug options exist for Treatment-resistant depression. Alternatives within the nmda receptor antagonist (antidepressant) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.